Merlin Biosciences

A venture-capital firm founded in 1996 by biotech entrepeneur Christopher Evans, Merlin Biosciences is one of the largest investors in the European bioscience market and has raised more than &euro;500 million in syndicated equity finance for its portfolio companies.

Many of the companies in which Merlin has invested have been struggling in a harsh environment for small biotech firms.

Its portfolio interests include theraputic cancer pharmaceuticals, viral vector vaccine delivery, and broad-spectrum antibiotics.

Personnel

 * Christopher Evans, Chariman and founder
 * Mark Clement, Chief Executive

Links

 * http://www.merlin-biosciences.com/